Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Research

| More

Maintain Reduce on Dr. Reddy's Labs - Valuations leave little room for disappointment - HDFC Securities

Posted On: 2020-05-21 14:27:01


Ms. Bansi Desai, Institutional Research Analyst, HDFC Securities.

Dr. Reddy's Labs (Q4FY20 Results Review): Valuations leave little room for disappointment. Maintain Reduce.
(TP Rs 3, 770, CMP Rs 3, 910, MCap Rs 650 bn)

Dr. Reddys' Q4 PAT came ahead of expectations led by strong revenue growth (+15% YoY, 6% beat) and tax write back. EBIDTA margins came in line as lower gross margins were offset by lower SG&A spends. Improved growth trajectory and cost control initiatives have led to EBIDTA margin expansion (~300bps) over the last three years. Going forward, while we continue to factor cost savings, a large part (~20%) of our FY22 estimates hinges on key product approvals in the US (gNuvaring, gCopaxone), the approval timelines for which remain uncertain. Despite factoring these launches and margin expansion as per company guidance, we don't see upside from current levels. The stock trades at 27x/21x FY21/22 EPS which leaves limited room for execution miss. We maintain Reduce rating with a revised TP of Rs3,770 based on 20x FY22 EPS.

Revenue beat, margins in line: Revenues grew at 15% YoY at Rs44.3bn as strong growth in US (+13% YoY, new launches, higher volumes), Europe (+80% YoY, +11% YoY, strong performance in Germany, new markets) offset muted growth in India (+5%YoY, logistics impact). EBIDTA margins came at 21.6% (down 216bps QoQ) as lower gross margins (adverse business mix, write offs) were partially offset by lower SG&A spend (-120bps QoQ).

Major part of US growth hinges on two key product approvals: We forecast the US business to register 14% revenue CAGR over the next two years and two key assets - gNuvaring and gCopaxone account for ~50%+ of growth in the same period. We factor these high value launches, along with sustained cost savings and factor ~350bps margin expansion over FY20-22e. Any delay in approval/launch timelines will impact our estimates.

Key call takeaways: a) Price erosion in US has stabilized, deflation to continue; b) gNuvaring and gCopaxone - CRL to be filed in few months; gVascepa - no hurdles on regulatory front; expects to launch 25 products in the US; c) Wockhardt deal closure expected in Q1FY21; d) Covid impact was neutral on revenues; e) Guidance: Gross margin: 52-54% of sales, R&D spend: 9-10% of sales, Capex: Rs10bn in FY21, Tax rate: 22%

Maintain Reduce, risks: We increase our EPS estimates by 3-7% for FY21/22 and revise our TP to Rs3,770 (from Rs3,330 earlier). Our TP is based on 20x FY22 EPS. Key upside risks: Lower price erosion in the US, higher growth in India and EM markets; faster than expected approvals for key products in the US.

Shares of DR.REDDY's LABORATORIES LTD. was last trading in BSE at Rs.3910.75 as compared to the previous close of Rs. 3699.55. The total number of shares traded during the day was 137220 in over 12937 trades.

The stock hit an intraday high of Rs. 3927.8 and intraday low of 3695.1. The net turnover during the day was Rs. 524998706.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Maintain ADD on Torrent Pharma - Stable performance, Resilient outlook - HDFC Securities

Analysis on ITC acquiring 100% equity stake in Sunrise Foods Pvt Ltd - HDFC Securities

Maintain ADD on Trent - Savings in Cost of Retailing > GM dilution - HDFC Securities

Maintain SELL on Avenue Supermarts - Un-DMARTesque! - HDFC Securities

Maintain ADD on DCB Bank - Attractive amidst visible headwinds - HDFC Securities

Maintain ADD on Colgate Palmolive - Muted Q4, signs of improving execution - HDFC Securities

Maintain BUY on JMC Projects - Long wait - HDFC Securities

Maintain BUY on JK Lakshmi Cement - Strong margin uptick; Healthy balance sheet - HDFC Securities

Maintain BUY on Kalpataru Power Transmission - Multiple triggers - HDFC Securities

Maintain ADD on BSE - Fighting back, cash support - HDFC Securities

Colgate Palmolive Q4FY20 Result First Cut - Miss on all fronts - HDFC Securities

Maintain ADD on L&T Infotech - Q4FY20 Results Review - HDFC Securities

Maintain BUY on UltraTech Cement - Robust margin and leverage performance - HDFC Securities

Maintain BUY on CDSL - Robust performance continues - HDFC Securities

Downgrade to REDUCE on Jubilant FoodWorks - Good franchise, a pause before run - HDFC Securities

ADD on Bajaj Auto - Resilient margins - HDFC Securities

RIL Right's Issue - Mr. Jyoti Roy, DVP Equity Strategist, Angel Broking Ltd

First Cut Analysis: BUY on UltraTech - Healthy results despite Covid impact - HDFC Securities

BUY on Escorts - Strengthening the core - HDFC Securities

Maintain ADD on Crompton Consumer - Q4FY20 Results Review - HDFC Securities

Maintain ADD on Zensar Technologies - Elusive quest for growth - HDFC Securities

Retain BUY on Nippon Life India Asset Management - Strong core despite market share loss! - HDFC Securities

Maintain ADD on L&T Technology Services - Enduring the ebbs and flows - HDFC Securities

Maintain Buy on Cipla - Positive outlook reaffirmed - HDFC Securities

Maintain BUY on Mahindra & Mahindra Financial Services - Pain inevitable, valuations attractive - HDFC Securities

Maintain SELL on ABB India - Long road to recovery - HDFC Securities

Maintain ADD on Mphasis - Positives outweigh the risks - HDFC Securities

Maintain REDUCE on Siemens - Headwinds remain - HDFC Securities

Maintain ADD on Havells - Recovery Interrupted by Covid - HDFC Securities

ADD on Kotak Mahindra Bank - Stronger than most, but expensive - HDFC Securities

Maintain REDUCE on Godrej Consumers - Weakness continues, exacerbated by Covid - HDFC Securities Institutional Research Desk

First Cut Analysis: Maruti Suzuki India Ltd Q4FY20 Results - HDFC Securities

Vedanta Limited - Voluntary Delisting Proposal - Angel Broking

Shree Cement - Strong show; Valuations remain expensive - Q4FY20 Result Review - HDFC Securities

ICICI Securities - Strong Quarter - Q4FY20 Result Review - HDFC Securities

Cyient - Crash landing - Q4FY20 Result Review - HDFC Securities

ICICI Bank - Well placed for a bumpy ride - Q4FY20 Result Review - HDFC Securities

RBL Bank - Risks to play out - Q4FY20 Result Review - HDFC Securities

Persistent Systems - Growth dichotomy - Q4FY20 Result Review - HDFC Securities

SBI Life Insurance - Challenging Year Ahead - Q4FY20 Result Review - HDFC Securities

Marico - Saffola saves the day - Q4FY20 Result Review - HDFC Securities

AU Small Finance Bank - Better placed vs. peers - Q4FY20 Result Review - HDFC Securities

Reliance Industries - A weak quarter but better visibility on Balance Sheet improvement - Result Review - HDFC Securities

ICICI Lombard - Uncertain times ahead - 4QFY20 Result Review - HDFC Securities

Reliance Retail - Top-line disappoints, margins surprise - Q4FY20 Result Review - HDFC Securities

Hindustan Unilever - Miss led by supply chain disruptions - Q4FY20 Results Review - HDFC Securities

Tech Mahindra - Signal dropped, not lost - Q4FY20 Result Review - HDFC Securities

RIL deal with Silver Lake - Dr. V K Vijayakumar, Chief Investment Strategist at Geojit Financial Services

Silver Lake's Investment in Reliance Jio - HDFC Securities

Mr. Jyoti Roy, DVP Equity Strategist, Angel Broking Ltd on the Silver Lake - JIO Deal







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019